Cancer Pain - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cancer Pain - Pipeline Review, H1 2016', provides an overview of the Cancer Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Pain - The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects - The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cancer Pain Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Cancer Pain Overview 12 Therapeutics Development 13 Pipeline Products for Cancer Pain - Overview 13 Pipeline Products for Cancer Pain - Comparative Analysis 14 Cancer Pain - Therapeutics under Development by Companies 15 Cancer Pain - Therapeutics under Investigation by Universities/Institutes 17 Cancer Pain - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Cancer Pain - Products under Development by Companies 22 Cancer Pain - Products under Investigation by Universities/Institutes 24 Cancer Pain - Companies Involved in Therapeutics Development 25 AngioChem Inc. 25 Aphios Corporation 26 AstraZeneca Plc 27 BCN Peptides, S.A. 28 Benitec Biopharma Limited 29 BioDelivery Sciences International, Inc. 30 ChironWells GmbH 31 Daewoong Pharmaceutical Co., Ltd. 32 Daiichi Sankyo Company, Limited 33 Fujimoto Pharmaceutical Corporation 34 Grunenthal GmbH 35 GW Pharmaceuticals Plc 36 Hisamitsu Pharmaceutical Co., Inc. 37 Immupharma Plc 38 IntelGenx Corp. 39 Kineta, Inc. 40 Kolon Life Science, Inc. 41 Neurocentrx Pharma Ltd. 42 Nippon Kayaku Co., Ltd. 43 Orion Oyj 44 Pain Therapeutics, Inc. 45 Pfizer Inc. 46 Pharmaleads SA 47 Recordati S.p.A. 48 Ribomic Inc. 49 Trillium Therapeutics Inc. 50 Virobay Inc. 51 WEX Pharmaceuticals Inc. 52 Zynerba Pharmaceuticals, Inc. 53 Cancer Pain - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 58 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 ANG-2002 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 AQU-118 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 BBI-11008 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 buprenorphine hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 cebranopadol - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 crotalphine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 CSTI-200 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DD-04107 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 dexmedetomidine hydrochloride - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 dronabinol - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 dronabinol - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Drug for Cancer Neuropathic Pain - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 DWJ-208 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 fentanyl - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 fentanyl citrate - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 fentanyl citrate - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 fentanyl citrate - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 HP-3150 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 HS-198 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 hydromorphone hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 INT-0010 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 IPP-102199 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 KLS-2020 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 methadone hydrochloride - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 nabiximols - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Nervarna - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 PL-265 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Q-201 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 QX-314 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 RBM-004 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 RBM-007 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 saracatinib difumarate - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 tanezumab - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 Tetrodotoxin - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 U-2902 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 VBY-825 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 zucapsaicin - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 ZYN-001 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Cancer Pain - Recent Pipeline Updates 123 Cancer Pain - Dormant Projects 137 Cancer Pain - Discontinued Products 141 Cancer Pain - Product Development Milestones 142 Featured News & Press Releases 142 Mar 31, 2016: Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride 142 Oct 27, 2015: GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex Phase 3 Cancer Pain Trials 142 Aug 13, 2015: Biodelivery Sciences Announces FDA Approval Of New Formulation Of Onsolis (Fentanyl Buccal Soluble Film) CII 143 Jan 27, 2015: BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda 144 Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement 145 Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain 145 Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 146 Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 146 Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 147 Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation 147 Appendix 148 Methodology 148 Coverage 148 Secondary Research 148 Primary Research 148 Expert Panel Validation 148 Contact Us 148 Disclaimer 149
List of Tables
Number of Products under Development for Cancer Pain, H1 2016 13 Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Cancer Pain - Pipeline by AngioChem Inc., H1 2016 25 Cancer Pain - Pipeline by Aphios Corporation, H1 2016 26 Cancer Pain - Pipeline by AstraZeneca Plc, H1 2016 27 Cancer Pain - Pipeline by BCN Peptides, S.A., H1 2016 28 Cancer Pain - Pipeline by Benitec Biopharma Limited, H1 2016 29 Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016 30 Cancer Pain - Pipeline by ChironWells GmbH, H1 2016 31 Cancer Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 32 Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 33 Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H1 2016 34 Cancer Pain - Pipeline by Grunenthal GmbH, H1 2016 35 Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016 36 Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 37 Cancer Pain - Pipeline by Immupharma Plc, H1 2016 38 Cancer Pain - Pipeline by IntelGenx Corp., H1 2016 39 Cancer Pain - Pipeline by Kineta, Inc., H1 2016 40 Cancer Pain - Pipeline by Kolon Life Science, Inc., H1 2016 41 Cancer Pain - Pipeline by Neurocentrx Pharma Ltd., H1 2016 42 Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 43 Cancer Pain - Pipeline by Orion Oyj, H1 2016 44 Cancer Pain - Pipeline by Pain Therapeutics, Inc., H1 2016 45 Cancer Pain - Pipeline by Pfizer Inc., H1 2016 46 Cancer Pain - Pipeline by Pharmaleads SA, H1 2016 47 Cancer Pain - Pipeline by Recordati S.p.A., H1 2016 48 Cancer Pain - Pipeline by Ribomic Inc., H1 2016 49 Cancer Pain - Pipeline by Trillium Therapeutics Inc., H1 2016 50 Cancer Pain - Pipeline by Virobay Inc., H1 2016 51 Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2016 52 Cancer Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 53 Assessment by Monotherapy Products, H1 2016 54 Number of Products by Stage and Target, H1 2016 56 Number of Products by Stage and Mechanism of Action, H1 2016 59 Number of Products by Stage and Route of Administration, H1 2016 62 Number of Products by Stage and Molecule Type, H1 2016 64 Cancer Pain Therapeutics - Recent Pipeline Updates, H1 2016 123 Cancer Pain - Dormant Projects, H1 2016 137 Cancer Pain - Dormant Projects (Contd..1), H1 2016 138 Cancer Pain - Dormant Projects (Contd..2), H1 2016 139 Cancer Pain - Dormant Projects (Contd..3), H1 2016 140 Cancer Pain - Discontinued Products, H1 2016 141
List of Figures
Number of Products under Development for Cancer Pain, H1 2016 13 Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 20 Assessment by Monotherapy Products, H1 2016 54 Number of Products by Top 10 Targets, H1 2016 55 Number of Products by Stage and Top 10 Targets, H1 2016 55 Number of Products by Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Top 10 Routes of Administration, H1 2016 61 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 61 Number of Products by Molecule Types, H1 2016 63 Number of Products by Stage and Molecule Types, H1 2016 63
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.